Clinical Stabilization of Hypercapnia: NIPPV v HVNI

NACompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

November 11, 2020

Primary Completion Date

May 26, 2023

Study Completion Date

June 22, 2023

Conditions
Hypercapnic Respiratory FailureChronic Obstructive Pulmonary DiseaseDyspneaHypercapnic Acidosis
Interventions
DEVICE

High Velocity Nasal Insufflation (HVNI)

The purpose of this intervention is to evaluate the efficacy of HVNI in clinically stabilizing patients presenting with hypercapnic respiratory distress.

DEVICE

Noninvasive Positive Pressure Ventilation (NIPPV)

The purpose of this intervention is to evaluate the efficacy of NIPPV in clinically stabilizing patients presenting with hypercapnic respiratory distress.

Trial Locations (7)

20037

George Washington University Hospital, Washington D.C.

21201

University of Maryland, Baltimore

37403

Erlanger Health System, Chattanooga

91405

Valley Presbyterian Hospital, Los Angeles

93030

Dignity Health - St. John's Regional Medical Center, Oxnard

98431

Madigan Army Medical Center, Tacoma

08103

Cooper University Hospital, Camden

All Listed Sponsors
collaborator

Erlanger Baroness Hospital

OTHER_GOV

collaborator

The Cooper Health System

OTHER

collaborator

Dignity Health Medical Foundation

OTHER

collaborator

George Washington University

OTHER

collaborator

Madigan Army Medical Center

FED

collaborator

Valley Presbyterian Hospital

OTHER

collaborator

University of Maryland

OTHER

lead

Vapotherm, Inc.

INDUSTRY

NCT04709562 - Clinical Stabilization of Hypercapnia: NIPPV v HVNI | Biotech Hunter | Biotech Hunter